Breast cancer is the most frequently diagnosed life-threatening cancer in women. Despite significant advances in the treatment of early breast cancer, 30% of women go on to develop metastatic disease and recurrence. Approximately 20% of breast cancers are human epidermal growth factor receptor 2 positive (HER2+), which correlates with a more aggressive phenotype that metastasizes rapidly and recurs frequently.
While resection and adjuvant radiation may occasionally be an option to treat metastases in certain sites, in general, HER2 + metastatic breast cancer must be approached systemically so that treatment may reach all disease sites. Management of HER2+ metastatic disease requires careful sequencing considerations to help maximize overall survival while minimizing toxicity and adverse reactions.
Test your knowledge of HER2+ metastatic breast cancer management with this quick quiz.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Winston Tan. Fast Five Quiz: HER2+ Metastatic Breast Cancer Management - Medscape - Jan 10, 2022.